Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview
QualityStocks today announces the availability of a new audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTC: NPHC), a biotech company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The interview can be heard at http://www.QualityStocks.net/interview-nphc.php.
Nutra Pharma is developing a broad product platform for numerous indications, and it currently has 21 patents in its intellectual property portfolio. The QualityStocks interview begins with Deitsch describing Nutra Pharma’s business model and three key patents: one for autoimmune disease, one for antiviral therapeutics, and one for the treatment of pain. Nutra Pharma also has launched a line of over-the-counter (OTC) pain drugs (Nyloxin, for humans, and Pet Pain-Away, for dogs and cats), which financially buoy the research and development of the company’s potential blockbuster drugs.
“The sales of these OTC drugs produce revenue that mitigates the risk to investors and actually pays for the clinical research as we move the products forward,” Deitsch explains.
Before highlighting other individuals on the company’s management team, Deitsch, a seasoned biochemist, adjunct professor and author, describes his extensive professional background, which includes 25 years researching drugs derived from venomous animals, and employment with the world’s largest manufacturer of dietary supplements, for which he formulated more than 50 dietary supplements and conducted more than 50 clinical studies.
The topic then turns to several of Nutra Pharma’s historical milestones, its strategies to increase domestic and international reach, and how it transitioned into its current line of operations. One of Nutra Pharma’s largest achievements to-date, says Deitsch, is obtaining Orphan Drug Status from the U.S. FDA for RPI-78M for pediatric multiple sclerosis (MS).
“We went back and forth with the FDA for several weeks, but it only took about five weeks from the point where we applied for Orphan Drug Status to actually getting the Orphan Status designation, which is huge,” he says. “It really means the FDA saw the value that we had in our drug.”
Deitsch next describes the advantages of this corporate achievement, how it prepares the company to move into a larger market, and how it differs from currently available drugs.
“With our drug … we stop the hyper immune response that causes multiple sclerosis. So from the day you start taking the drug, what we’ve seen in our clinical research is that your disease progression stops and over time your symptoms improve. So this is a game-changer when it comes to treating any auto-immune disease, but certainly when it comes to treating multiple sclerosis. We really believe that we’re going to prove this in our clinical studies and then we’ll seek a licensed partner,” he says.
In the near future, Nutra Pharma plans on commencing and completing phase II clinical studies of RPI-78M and building a strong domestic sales force to increase sales and availability of its Nyloxin and Pet Pain-Away Products.
“I think that as we get this message out there we’re going to see a huge increase in sales that of course is not only going to help bring the company to the next level, it’s going to help us create more and more products for our platform that we’re going to be able to license to big pharma in the next 12-18 months,” concludes Deitsch.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
QualityStocks today announces the availability of a new audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTC: NPHC), a biotech company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The interview can be heard at http://www.QualityStocks.net/interview-nphc.php.
Nutra Pharma is developing a broad product platform for numerous indications, and it currently has 21 patents in its intellectual property portfolio. The QualityStocks interview begins with Deitsch describing Nutra Pharma’s business model and three key patents: one for autoimmune disease, one for antiviral therapeutics, and one for the treatment of pain. Nutra Pharma also has launched a line of over-the-counter (OTC) pain drugs (Nyloxin, for humans, and Pet Pain-Away, for dogs and cats), which financially buoy the research and development of the company’s potential blockbuster drugs.
“The sales of these OTC drugs produce revenue that mitigates the risk to investors and actually pays for the clinical research as we move the products forward,” Deitsch explains.
Before highlighting other individuals on the company’s management team, Deitsch, a seasoned biochemist, adjunct professor and author, describes his extensive professional background, which includes 25 years researching drugs derived from venomous animals, and employment with the world’s largest manufacturer of dietary supplements, for which he formulated more than 50 dietary supplements and conducted more than 50 clinical studies.
The topic then turns to several of Nutra Pharma’s historical milestones, its strategies to increase domestic and international reach, and how it transitioned into its current line of operations. One of Nutra Pharma’s largest achievements to-date, says Deitsch, is obtaining Orphan Drug Status from the U.S. FDA for RPI-78M for pediatric multiple sclerosis (MS).
“We went back and forth with the FDA for several weeks, but it only took about five weeks from the point where we applied for Orphan Drug Status to actually getting the Orphan Status designation, which is huge,” he says. “It really means the FDA saw the value that we had in our drug.”
Deitsch next describes the advantages of this corporate achievement, how it prepares the company to move into a larger market, and how it differs from currently available drugs.
“With our drug … we stop the hyper immune response that causes multiple sclerosis. So from the day you start taking the drug, what we’ve seen in our clinical research is that your disease progression stops and over time your symptoms improve. So this is a game-changer when it comes to treating any auto-immune disease, but certainly when it comes to treating multiple sclerosis. We really believe that we’re going to prove this in our clinical studies and then we’ll seek a licensed partner,” he says.
In the near future, Nutra Pharma plans on commencing and completing phase II clinical studies of RPI-78M and building a strong domestic sales force to increase sales and availability of its Nyloxin and Pet Pain-Away Products.
“I think that as we get this message out there we’re going to see a huge increase in sales that of course is not only going to help bring the company to the next level, it’s going to help us create more and more products for our platform that we’re going to be able to license to big pharma in the next 12-18 months,” concludes Deitsch.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
